897732-75-1

Usage

Uses

Used in Pharmaceutical Industry:
3-PyridinaMine, 2-Methyl-6-(Methylsulfonyl)is used as an antimalarial medication for the prevention and treatment of malaria. It is particularly effective in regions where the malaria parasites have developed resistance to other drugs, making it a vital tool in the global health effort to combat this disease.
Used in Travel Medicine:
Mefloquine is used as a prophylactic medication for travelers visiting areas where malaria is endemic. It helps to reduce the risk of contracting the disease, ensuring the health and safety of individuals in high-risk environments.
Used in Public Health Initiatives:
3-PyridinaMine, 2-Methyl-6-(Methylsulfonyl)is utilized in public health programs aimed at controlling and eradicating malaria. Its role in both treatment and prevention contributes to the broader strategy of reducing the incidence and impact of malaria on affected populations.
Used in Research and Development:
Mefloquine is also used in research settings to study the mechanisms of action against the malaria parasite and to develop new antimalarial drugs or drug combinations that may be more effective or have fewer side effects. This ongoing research is crucial for staying ahead of the evolving resistance patterns in malaria parasites.

InChI:InChI=1S/C7H10N2O2S/c1-5-6(8)3-4-7(9-5)12(2,10)11/h3-4H,8H2,1-2H3

Upstream product

• 20277-69-4 sodium methansulfinate 
• 126325-47-1 3-amino-6-bromo-2-methylpyridine 
• 66799-59-5 6-methanesulfonyl-2-methyl-3-nitro-pyridine 

Downstream Products

• 897732-93-3 APD597 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF 4- [6-(6-METHANESULFONYL-2-METHYL-PYRIDIN-3-YLAMINO) -5-METHOXY-PYRIMIDIN-4-YLOXY]-PIPERIDINE-1-CARBOXYLIC ACID ISOPROPYL ESTER

The present invention is directed to a process for the preparation of 4-[6- (6-methanesulfonyl-2-methyl-pyhdin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]- piperidine-1 -carboxylic acid isopropyl ester, useful as glucose dependent insulinotropic receptor agonist, for the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

GPR119 Receptor Agonists

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as inhibitors of GPR119 for the treatment or prevention of metabolic, cardiovascular, and metabolic diseases.

MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methyl-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester, pharmaceutically acceptable salts, solvates and hydrates thereof that are modulators of glucose metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.